Serum uric acid and lipid levels while taking topiramate for migraine

Headache

Volumn 48, Issue 7, 2008, Pages 1056-1060

  Koçer, Abdulkadir ^a   Dikici, Süber ^b   Atakay, Selcuk ^a   Okuyucu, Şefika ^a  

^a DUZCE UNIVERSITY   (Turkey)

^b Duzce Ataturk State Hospital   (Turkey)

Author keywords

Antiepileptic treatment; Cholesterol; Migraine; Topiramate; Triglyceride; Uric acid

Indexed keywords

ANTICONVULSIVE AGENT; CHOLESTEROL; LIPID; TOPIRAMATE; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERURICEMIA; LIPID BLOOD LEVEL; MALE; MIGRAINE; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FRUCTOSE; HUMANS; HYPERURICEMIA; LIPIDS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; TRIGLYCERIDES; URIC ACID;

EID: 46749096367     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.01008.x     Document Type: Article

References (27)

1. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004 61 : 490 495.
2. Peres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. J Headache Pain. 2006 7 : 185 187.
3. Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006 48 : 555 563.
4. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: A randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006 28 : 1002 1011.
5. Erfurth A, Kuhn G. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: Effects on mood, weight and serum lipids. Neuropsychobiology. 2000 42 (Suppl. 1 50 51.
6. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001 42 : 1002 1006.
7. Rosenfeld WE. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997 19 : 1294 1308.
8. Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia. 2002 43 : 1168 1171.
9. Otom S, Batieneh H, Hassan Z, Daoud A. Effects of long-term use topiramate on fertility and growth parameter in adult male rats. Neuroendocrinol Lett. 2004 25 : 351 355.
10. Bray GA, Hollander P, Klein S, et al, for the Topiramate Research Group. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003 11 : 722 733.
11. Murray L, ed. Physicians' Desk Reference 2004. Montvale : Thompson PDR 2004.
12. Natsch S, Hekster YA, Keyser A, Dekers CL, Meinardi H, Renier WO. Newer anticonvülsant drugs: Role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf. 1997 17 : 228 224.
13. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABAmediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997 28 : 167 179.
14. Greenberg A. Diuretic complications. Am J Med Sci. 2000 319 : 10 24.
15. Ayvazian JH, Ayvazian LF. A study of the hyperuricemia induced by hydrochlorthiazide and acetazolamide separately and in combination. J Clin Invest. 1961 40 : 1961 1966.
16. Plaisted CS, Istfan NW. Metabolic abnormalities of obesity. In : Blackburn GL, Kanders BS, eds. Obesity Pathophysiology, Psychology, and Treatment. Boston, MA : Chapman & Hall 1994 : 80.
17. Oyama C, Takahashi T, Oyamada M, et al. Serum uric acid as an obesity-related indicator in early adolescence. Tohoku J Exp Med. 2006 209 : 257 262.
18. Brown DW, Ketter TA, Crumlish J, Post RM. Carbamazepine induced increases in total serum cholesterol: Clinical and theoretical implications. J Clin Psychopharmacol. 1992 12 : 431 437.
19. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults. Epilepsia. 2000 41 : 66 66.
20. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003 11 : 556 562.
21. Isojarvi JI, Pakarinen AJ, Myllyla VV. Serum lipid levels during carbamazepine medication. A prospective study. Arch Neurol. 1993 50 : 590 593.
22. Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit. 2004 10 : 50 52.
23. Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology. 1995 45 : 1155 1157.
24. Spinler SA. Challenges associated with metabolic syndrome. Pharmacotherapy. 2006 26 : 209 217.
25. Zieve FJ. The metabolic syndrome: Diagnosis and treatment. Clin Cornerstone. 2004 6 : 5 13.
26. Bigal ME, Lieberman JN, Lipton RB. Obesity and migraine. A population study. Neurology. 2006 66 : 545 550.
27. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004 25 : 4 9.